Company intelligence
QIAGEN
About QIAGEN
Every day, more than 500,000 customers around the world rely on QIAGEN solutions to extract meaning from genetic material quickly, confidently and accurately. Whether the goal is driving discovery, diagnosing disease or guiding treatment decisions, QIAGEN technologies help make the process reliable, fast and more impactful. These customers include young scientists, pharma R&D teams, clinical labs and more than 35 Nobel Prize winners, all choosing QIAGEN to help advance science and improve outcomes. QIAGEN is not just a supplier of kits and instruments. We are a partner in progress, backed by a deep commitment to science and better healthcare. In a world where the stakes continue to rise and the questions grow more complex, QIAGEN exists to accelerate the breakthroughs science and society urgently need, by advancing science and improving healthcare. This is how we make improvements in life possible. Discover more at ➡️ http://www.qiagen.com
Verified activity
Signals from QIAGEN
9 published signals
Products & Services
QIAGEN announced that CarisDetect is a new product launched for early detection of cancer.
Reported by Abhishek Sharma
Products & Services
QIAGEN announced that QIAsymphony Connect achieves higher nucleic acid concentrations than its predecessor, even though both use magnetic bead-based extraction and the same chemistry.
Reported by QIAGEN
Presence & Recognition
QIAGEN is hosting a rapid-fire, 20-minute live virtual event on September 10 for QIAsymphony Connect.
Reported by QIAGEN
People
QIAGEN welcomed Ruth Forman and Mahedah Rehman as interns for the first cohort of the NIHR Biomedical Research Centre Manchester, working across projects and delivering documentation.
Reported by QIAGEN
People
QIAGEN opened applications for the Q1 2027 intake of the NIHR Biomedical Research Centre Manchester cohort, with applications opening on 14th September.
Reported by QIAGEN
Presence & Recognition
QIAGEN is hosting the Qrious show QIAsymphony Connect on tour: Voices from the lab on September 10, 2026, featuring a virtual demo of the instrument and early access users from Myriad Genetics and Institute of Pathology and Genetics (IPG), Belgium.
Reported by Shu Boles, PhD MBA
Legal & Regulatory
QIAGEN launched QIAsymphony Connect, the next generation of its automated clinical sample preparation platform, following FDA listing in the U.S. and EUDAMED listing in Europe.
Reported by Fernando Beils
People
QIAGEN appointed Jonathan Pratt as CEO.
Reported by QIAGEN
People
QIAGEN appointed Jonathan Pratt as CEO.
Reported by Jonathan Pratt